

# Index

## A

- Acinetobacter baumannii*
  - aminoglycoside-modifying enzymes, 52
  - antimicrobial-resistance mechanisms, 53
  - carbapenem resistance, 53
  - clinical significance, 58
  - description, 58
  - environmental transmission, 61
  - outbreak, 58
- Acquired immunodeficiency syndrome (AIDS). *See* Human immunodeficiency virus (HIV)
- Active surveillance, MDROs, 62
- Acute adenolymphangitis (ADL), 234
- Aedes aegypti*, 215, 230, 298, 304
- Aedes albopictus*, 298
- Anopheles gambiae*
  - Africa, 211
  - insecticide resistance, 212, 213
  - metabolic resistance, 214
- Antibiotic(s)
  - aminoglycosides analogs, 67–68
  - $\beta$ -lactamase inhibitors, 68
  - ceftaroline, 67
  - ceftobiprole, 67
  - diminished effectiveness, 66
  - dry pipeline, 66–67
  - fosfomycin, 68
  - high-throughput screening, 67
  - marketing, 67
  - NXL 104, 68
  - optimization, 68–69
  - polymyxins, 68
  - profitability, 66
  - quinalactams, 68

## resistance

- A. baumannii*, 58
- economic impact, 48
- Enterobacter* species, 59
- ESKAPE organisms, 52–54
- genetic variability, role of, 50–51
- Klebsiella* species, 57
- MRSA, 54–56
- nonhuman sources, 64–66
- origin, 48–49
- P. aeruginosa*, 58–59
- and uses, 49–50
- VRE, 56
- stewardship, 69–71
- Antimicrobial stewardship program, 70
- Antiretroviral therapy (ART), 10, 12–14

## B

- Bilharzia. *See* Schistosomiasis
- Brugia malayi*
  - biology, 232, 233
  - epidemiology, 230
  - geographic distribution, 229
  - subclinical patent infection, 233–234
  - TPE, 236
- Brugia timori*
  - biology, 232
  - clinical manifestations, 233
  - epidemiology, 230

## C

- Carbapenem-resistant *K. pneumoniae* (CRKP), 46, 60, 62, 63

Case fatality rate (CFR), 150–151

**Cholera**

cholera toxin (CTX), 145–146

environmental factors

cholera-climate interactions paradigm,  
167–168

climate variation, 166

copepods, 165–166

global temperature fluctuations,  
166–167

phytoplankton and crustaceans, 165

epidemiology

CFR, 150–151

IHR, 147–148

indiscriminate infection patterns,  
149–150

WHO, 147, 148

evolutionary factors, 168–170

Haitian population, 144

hierarchical environmental model,  
152, 153

**ORT**

antibiotics, 174

CFR, 173

CTU, 174

description, 170

diarrhea mortality rate, 172

gutamine, 172–173

micronutrient deficiency, 173

orchestrated traditional practice, 170

RO-ORS, 171–172

saline-glucose-potassium solution,  
170–171

WHO cholera vaccination

recommendations, 174, 175

WHO-ORS, 171–172

transmission

host susceptibility, 153–154

microbiology and environment,  
151–153

*V. cholerae* (see *Vibrio cholerae*)

water and sanitation concerns

Asiatic cholera, 154

chlorination, 158–159

death rates, Ohio and USA, 155–157

disruptions, natural and complex  
disasters, 159–164

health-care system, 158

IDP camps, 159–160

infant death rates, England and Wales,  
154, 155

miasma theory, 154

migrating populations, 164–165

secondary transmission, 158–159

Voronoi diagram, London, 154, 156

Zimbabwe National Water Authority  
(ZINWA), 158

Cholera treatment units (CTU), 174

Chyluria, 236

Copepods, 165–166

Cutaneous leishmaniasis (CL)

caused by, 243

description, 244

diagnosis, 247

incidence, 244

reservoir host control, 254

risk factors, 245

treatment, 251–252

vaccines, 253

**D**

Darunavir (DRV), 11, 17

Dengue hemorrhagic fever (DHF)

diagnosis, 302

epidemiology, 298–299

mortality, 302

prevalence, 297

primary pathophysiological  
abnormality, 301

risk factor, 300

Dengue shock syndrome (DSS)

description, 302

mortality, 302

primary pathophysiological  
abnormality, 301

risk factor, 300

Dengue virus infection

*Aedes aegypti*, 298

*Aedes albopictus*, 298

climatic influences, 300

clinical management, 303

clinical manifestations

asymptomatic infections, 301

classic dengue fever, 301

DHF, 302

DSS, 302

control strategies, 304

countries/areas at risk, 298, 299

diagnosis, 302–303

differential diagnosis, 303

Flaviviridae family, 297

pathogenesis, 300–301

prevalence, 297

responsible factors, 299

risk for travelers, 300

RNA genomes, 297–298

serotypes, 297

vaccination, 304–305

WHO, 299, 302

Dermatolymphangioadenitis (DLA), 234  
 DHF. *See* Dengue hemorrhagic fever (DHF)  
 Diffuse cutaneous leishmaniasis, 244  
 DLA. *See* Dermatolymphangioadenitis (DLA)  
 Drug-resistant malaria  
   epidemiology, 203–204  
   host factors, 206–207  
   parasitic factors, 208–210  
   pharmacological factors, 207–208  
   population dynamics, 205  
   Thailand-Cambodia border, 203–206  
 DSS. *See* Dengue shock syndrome (DSS)

## E

Emtricitabine, 11, 17  
 Enfuvirtide, 11, 18  
 Enteric epidemics. *See* Cholera  
*Enterobacter* species, 59  
 ESKAPE organisms  
   antibiotic resistance mechanisms, 52–54  
   description, 46  
 Extended-spectrum  $\beta$ -lactamases (ESBLs)  
   AmpC  $\beta$ -lactamases, 54  
   production, 46, 48, 50  
 Extensively drug-resistant tuberculosis  
   (XDR-TB)  
   evolution, 95  
   HIV coinfection, 102–103  
   KwaZulu-Natal strains, molecular  
     analysis of, 95  
   management of, 96–100  
   prevalence, 90  
   second-line drugs, susceptibility  
     testing of, 90  
   selection basis, 95  
   terminology, 89  
   treatment, 100–101  
   WHO report, 90, 91

## F

Fosamprenavir, 17

## G

Gastrointestinal disease, 266  
 Genitourinary disease  
   LF, 236  
   schistosomiasis, 266–267  
 Gram-positive organisms. *See* Methicillin-resistant *Staphylococcus aureus* (MRSA); Vancomycin-resistant *Enterococcus faecium* (VRE)

## H

H5N1 Avian influenza pandemics, 127  
 H1N1 influenza pandemics, 127  
 Human immunodeficiency virus (HIV)  
   antiretroviral drugs  
     development, 10  
     recommended regimens, 17–18  
 Australia, 7  
 biological mechanisms  
   lentiviruses characterization, 8  
   viral entry and replication, 9  
   viral variation and evolution, 9–10  
 Caribbean, 6–7  
 Central America, 6  
 Central Asia, 5  
 combination prevention  
   behavior change, 21  
   epidemiology, 20  
   future perspectives, 23–24  
   HPTN 052 trial, 23  
   packages, 22  
   sociopolitical obstacles, 20–21  
   testing and linkage care, 22–23  
 East Asia, 3–4  
 Eastern Europe, 5  
 licensed antiretroviral therapy,  
   11, 15–16  
 MDR-TB, coinfection with, 102–103  
 Middle East, 5  
 morbidity and mortality, 3  
 mother-to-child transmission, 3  
 North Africa, 5  
 North America, 5–6  
 Oceania, 7  
 patient management issues, 18–19  
 prevalence rates, 2  
 South America, 6  
 South Asia, 4–5  
 Southeast Asia, 3–4  
 sub-Saharan Africa, 3–4  
 urbanization  
   Asian countries, 132–133  
   opportunistic infection, 133  
   prevalence, 132  
   sub-Saharan Africa, 133  
 Western Europe, 5–6  
 XDR-TB, coinfection with, 102–103

## I

Internally displaced population (IDP) camps,  
 159–160  
 International Health Regulations (IHR),  
 147–148

**K**

*Klebsiella* species, 57

**L**

Leishmaniasis

- characterisation, 244–245
- description, 243
- diagnosis, 245–247
- incidence, 244
- reservoir host control, 254
- risk factors, 245
- transmission, 244
- treatment, 247–253
- vaccines, 253–254
- vector control, 254

Lentiviruses, HIV, 8

LF. *See* Lymphatic filariasis (LF)

Licensed antiretroviral therapy, HIV, 11, 15–16

Liver disease, 266

Lopinavir, 11, 17

Lymphatic filariasis (LF)

- biology, 232–233
- characterisation, 229
- clinical aspects
  - ADL, 234
  - DLA, 234
  - genitourinary system, 236
  - lymphedema, 234–235
  - subclinical patent infection, 233–234
  - TPE, 236
- drug regimens, 237
- epidemiology, 230, 232
- filarial parasites of humans, 229, 231
- morbidity control, 237
- obstacles, 238–239
- protective measures, 238
- vaccines, 237–238

**M**

Malaria

- antifolate drugs, 210
- antimalarial drug resistance, 203
- apicoplast, 218
- artemisinin-resistant, 206, 218
- biosafety issues, 215
- blood-stage vaccines, 217
- challenges, 213–215
- chloroquine resistance reversal
  - agents, 218
- description, 199
- drug-resistant
  - epidemiology, 203–204

- host factors, 206–207
- parasitic factors, 208–210
- pharmacological factors, 207–208
- population dynamics, 205
  - Thailand-Cambodia border, 203–206

- effective chemotherapy, 201
- eventual elimination, goal of, 201–202
- global eradication program, 201
- historical records, 200
- microbiology, 200
- preerythrocytic stage vaccine, 216
- rapid diagnostic tests (RDTs), 217–218
- resource-poor countries, 220–221
- transmission-blocking vaccine (TBV), 216–217
- vector factors, 211–212
- vector resistance, 212–213

Maraviroc, 11, 17–18

MDROs. *See* Multidrug-resistant organisms (MDROs)

Methicillin-resistant *Staphylococcus aureus* (MRSA)

- active surveillance, 62
- characterisation, 54
- community-associated, 55
- decolonization, 63
- environmental contamination, 61
- healthcare workers acquisition, 60
- hospital-acquired, 55
- vs. MSSA, 47
- nosocomial infections, 54–55

Metrifonate, 271

MRSA. *See* Methicillin-resistant

*Staphylococcus aureus* (MRSA)

Muco-cutaneous leishmaniasis (MCL)

- caused by, 243
- characterisation, 244

Multidrug-resistant organisms (MDROs)

- antibiotic resistance
  - Acinetobacter baumannii*, 58
  - economic impact, 48
  - Enterobacter* species, 59
  - Klebsiella* species, 57
  - mechanisms of, 50–54
  - MRSA, 54–56
  - nonhuman sources, 64–66
  - origin, 48–49
  - P. aeruginosa*, 58–59
  - and uses, 49–50
  - VRE, 56
- clinical significance
  - MDR gram-negative bacilli, 47–48
  - MRSA, 47
  - VRE, 47

- description, 45
  - prevention of transmission
    - active surveillance, 62
    - decolonization strategies, 63–64
    - environmental contamination, 61
    - hand hygiene and contact isolation, 59–61
  - Multidrug-resistant tuberculosis (MDR-TB)
    - Beijing genotype family, 93–94
    - development factors, 92
    - drug therapy, 97, 98
    - evolution, 88
    - fluoroquinolones, 99
    - genetics of, 93–96
    - global distribution, 89, 90
    - global initiatives, 111
    - HIV coinfection, 102–103
    - management of, 96–100
    - prevalence, 88–89
    - risk factors, 99
  - Mycobacterium tuberculosis*, 88, 130
- N**
- Neuroschistosomiasis, 267
- O**
- Oral rehydration therapy (ORT)
    - antibiotics, 174
    - CFR, 173
    - CTU, 174
    - description, 170
    - diarrhea mortality rate, 172
    - glutamine, 172–173
    - micronutrient deficiency, 173
    - orchestrated traditional practice, 170
    - RO-ORS, 171–172
    - saline-glucose-potassium solution, 170–171
    - WHO cholera vaccination
      - recommendations, 174, 175
    - WHO-ORS, 171–172
  - Oxamniquine, 271
- P**
- PKDL. *See* Post-kala-azar dermal leishmaniasis (PKDL)
  - Plague pandemics, 125
  - Plasmodium falciparum*
    - Cambodia-Thailand border, 219
    - chloroquine-resistant, 201, 203, 204
    - in vitro* experiments, 208, 209
    - microbiology, 200
    - multidrug resistance gene, 210
    - preerythrocyte stage vaccine, 216
    - primaquine, 210
    - sporogony duration, 211
  - Plasmodium malariae*, 200, 203
  - Plasmodium ovale*, 200, 210
  - Plasmodium vivax*
    - antigen vaccination, 217
    - drug resistance, 203
    - microbiology, 200
    - primaquine, 210
    - transmission-blocking vaccine, 216
  - Post-kala-azar dermal leishmaniasis (PKDL)
    - description, 245
    - recommended regimens, 248
    - treatment, 251
    - vaccines, 253
  - Protein energy malnutrition (PEM), 162, 163
  - Pseudomonas aeruginosa*, 58–59
- R**
- Raltegravir, 11, 17
  - Reduced-osmolar ORS (RO-ORS), 171–172
- S**
- SARS. *See* Severe acute respiratory syndrome (SARS)
  - Schistosomiasis
    - acute disease, 265
    - artemether, 271
    - chronic
      - gastrointestinal disease, 266
      - genitourinary disease, 266–267
      - liver disease, 266
      - neurological outcome, 267–268
      - neuroschistosomiasis, 267
    - control programmes
      - categories, 277–278
      - in China, 284
      - limitations, 284
      - mathematical modelling, 280, 282–283
      - spatial modelling, 280
    - corticosteroids, 271
    - description, 261
    - diagnosis
      - formalin-based techniques, 268
      - indirect methods, 269
      - Kato-Katz thick smear stool examination, 268
      - loop-mediated isothermal amplification, 269
      - miracidium-hatching test, 268

- Schistosomiasis (*cont.*)
- polymerase chain reaction based assays, 269
  - urine-CCA strip, 270
  - early manifestations, 265
  - epidemiology, 264–265
  - health education/promotion programmes, 278
  - immune response, 272–274
  - integrated control package, 284–285
  - lifecycle, 262, 263
  - metrifonate, 271
  - oxamniquine, 271
  - praziquantel, 270–271
  - recommended preventive chemotherapy strategy, 278, 279
  - transmission, 263
  - vaccine development
    - antigen discovery, 276
    - codon optimization, 276
    - epitope/protein/multivalent vaccines, 276
    - S. haematobium*, 274–275
    - S. japonicum*, 275–276
    - S. mansoni*, 274–275
- Schistosomiasis haematobium*
- geographical distribution, 280
  - microscopic detection, 268
  - neurological complications, 267
  - preventive chemotherapy strategy, 278, 279
  - vs. SCC, 267
  - urinary tract disease, 266–267
  - vaccine development, 274–275
- Schistosomiasis japonicum*
- epidemiology, 281
  - genome sequencing, 276
  - mathematical models, 282
  - miracidium-hatching test, 268
  - transmission dynamic model, 282
  - vaccine development, 275
  - zoonotic transmission, 274
- Schistosomiasis mansoni*
- detection, 268
  - genome sequencing, 276
  - neurological complications, 267
  - vaccine development, 274–275
- Severe acute respiratory syndrome (SARS), 126
- Spanish influenza pandemics, 125–126
- Swine influenza pandemics, 126–127
- T**
- Tenofovir disoproxil fumarate (TDF), 17
- Tropical pulmonary eosinophilia (TPE), 236
- Tuberculosis (TB)
- Amplacor MTB test, 106
  - Amplified Mycobacterium Tuberculosis Direct (MTD) test, 106
  - antiretrovirals/second-line anti-TB drug interactions, 103, 104
  - anti-TB drugs, 108–110
  - bacterial airborne disease, 130
  - DOTS application, 105
  - drug resistance, emergence of
    - determinants, 93
    - factors, 92
    - mathematical models, 93
    - mechanisms, 91
    - treatment failure, 92
  - lipoarabinomannan ELISA test, 106
  - MDR-TB
    - Beijing genotype family, 93–94
    - development factors, 92
    - drug therapy, 97, 98
    - evolution, 88
    - fluoroquinolones, 99
    - genetics of, 93–96
    - global distribution, 89, 90
    - global initiatives, 111
    - HIV coinfection, 102–103
    - management of, 96–100
    - prevalence, 88–89
    - risk factors, 99
  - Millennium Development Goal, 87, 105
  - obstacles, 105
  - prevention of
    - BCG prime vaccination, 107
    - chronic social issues, 108
    - HIV pandemic, 108
    - INH treatment, 107–108
    - TB skin test (TST), 107
  - risk factor, 130
  - smear-negative diagnosis, 105
  - stop TB Partnership
    - accomplishments, 110–111
    - objectives, 103
  - XDR-TB
    - evolution, 95
    - HIV coinfection, 102–103
    - KwaZulu-Natal strains, molecular analysis of, 95
    - management of, 96–100
    - prevalence, 90
    - second-line drugs, susceptibility testing of, 90
    - selection basis, 95
    - terminology, 89
    - treatment, 100–101
    - WHO report, 90, 91

## U

## Urbanization

- bioterrorism, 134
- description, 120
- epidemics, mathematics of, 122–123
- epidemiology, emergence of, 122
- HIV
  - Asian countries, 132–133
  - opportunistic infection, 133
  - prevalence, 132
  - sub-Saharan Africa, 133
- infectious diseases, 121, 135–136
- noncommunicable disease, 137
- nosocomial infections, 134, 137
- pandemics
  - H5N1 Avian influenza, 127
  - H1N1 influenza, 127
  - plague, 125
  - SARS, 126
  - Spanish influenza, 125–126
  - swine influenza, 126–127
- respiratory infections, 130–131
- rural and urban populations
  - by development group, 120, 121
  - of the world, 119–120
- vaccines, 123–124
- vector-borne diseases, 129–130
- water and sanitation-related diseases, 128–129

## V

Vancomycin-resistant *Enterococcus faecium* (VRE)

- active surveillance, 62
- antibiotic resistance, 56
- and avoparcin, 65–66
- decolonization, 63
- environmental contamination, 61
- healthcare workers, 60
- outcomes, 47

*Vibrio cholerae*. See also Cholera

- campylobacter*, 152
- causative agent, 152
- classification, 151
- cytolysin, 146
- disrupted water sanitations restoration, 163–164
- El Tor biotype, 169–170
- gram-negative bacterium, 145
- hypervigilant hygienic practices, 161–162

## O antigen component, lipopolysaccharide, 168

- phylogenetic relationships, 161, 162
- protein energy malnutrition, 162, 163
- toxigenic, 146
- transmission
  - host susceptibility, 153–154
  - microbiology and environment, 151–153
- vibrio pathogenicity island (VPI), 169
- waterborne enterics, 161
- Visceral leishmaniasis (VL)
  - caused by, 243
  - characterisation, 244–245
  - diagnosis, 245–246
  - elimination programme, 255
  - HIV co-infection, 253
  - occurrence, 244
  - reservoir host control, 254
  - risk factor, 245
  - transmission, 244
  - treatment
    - amphotericin B deoxycholate, 249
    - combination drug therapy, 250–251
    - miltefosine, 249–250
    - paromomycin, 250
    - pentavalent antimonials, 247, 249
    - recommended regimens, 248
  - vaccines, 253
  - vector control, 254–255
- Voronoi diagram, 154, 156

## W

- Wolbachia* symbionts, 215
- Wuchereria bancrofti*
  - biology, 232–233
  - epidemiology, 230
  - geographic distribution, 229
  - subclinical patent infection, 233–234
  - TPE, 236

## X

- XDR-TB. See Extensively drug-resistant tuberculosis (XDR-TB)

## Z

- Zidovudine (ZDV), 10